original ) (raw )Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable
Byoung-Tak Zhang
Annals of the Rheumatic Diseases, 2007
View PDFchevron_right
Measuring the efficacy and effectiveness of rheumatoid arthritis therapy: time to change our thinking and adopt a new model
Fred Wolfe
The Journal of rheumatology, 2004
View PDFchevron_right
A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries
Joel Kremer
Seminars in Arthritis and Rheumatism, 2010
View PDFchevron_right
Randomized controlled trial design in rheumatoid arthritis: the past decade
jeremy sokolove
Arthritis Research & Therapy, 2009
View PDFchevron_right
Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design
Jacob Karsh
The Journal of …, 2011
View PDFchevron_right
Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster-Randomized Adalimumab Trial
john sampalis
Arthritis Care & Research, 2013
View PDFchevron_right
Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice
Markku J Kauppi
Rheumatology, 2017
View PDFchevron_right
The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials
Francesca Pregnolato
Therapeutic Advances in Musculoskeletal Disease, 2012
View PDFchevron_right
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
Catherine Reynolds
BMC musculoskeletal disorders, 2014
View PDFchevron_right
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study
Kirstine Amris
PLOS ONE, 2015
View PDFchevron_right
Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
Theodore Pincus
2004
View PDFchevron_right
Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when
Nasim ullah Khan
Arthritis & rheumatology (Hoboken, N.J.), 2014
View PDFchevron_right
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
Ana Rodrigues
Rheumatology, 2012
View PDFchevron_right
“Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients”
Joel Kremer
BMC Musculoskeletal Disorders, 2014
View PDFchevron_right
Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission
Theodore Pincus
The Journal of rheumatology, 2003
View PDFchevron_right
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Delphine Courvoisier , Axel Finckh
Annals of the Rheumatic Diseases, 2010
View PDFchevron_right
Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria
Bernadette Khoshaba , Janice Jimenez
Rheumatology (Oxford, England), 2005
View PDFchevron_right
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
Helena D'Elia
Annals of the rheumatic diseases, 2018
View PDFchevron_right
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy
M. Lunt , M. Bukhari
Rheumatology, 2010
View PDFchevron_right
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis
Alfons Den Broeder
Annals of the Rheumatic Diseases, 2003
View PDFchevron_right
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
Christopher McCabe
Health technology assessment (Winchester, England), 2018
View PDFchevron_right
On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al
Simone Gorter
2011
View PDFchevron_right
Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
Paul Emery
Rheumatology, 2012
View PDFchevron_right
The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference
Rosario Foti
Rheumatology (Oxford, England), 2018
View PDFchevron_right
The prevalence of underpowered randomized clinical trials in rheumatology
Kevin Pile
The Journal of rheumatology, 2005
View PDFchevron_right
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Alberto Alonso
BMC Musculoskeletal Disorders, 2008
View PDFchevron_right
Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry
Jean Dudler
Joint Bone Spine, 2013
View PDFchevron_right
Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
Joel Kremer
Arthritis & Rheumatism, 2005
View PDFchevron_right
Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
Fowzia Ibrahim
Health technology assessment (Winchester, England), 2014
View PDFchevron_right
anti-TNF agent? (TNF) agents after previous failure of an versus alternative anti-tumour necrosis factor arthritis benefits from switching to rituximab Which subgroup of patients with rheumatoid
Anca I Ciurea
2010
View PDFchevron_right
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations
Hasan Yazici
Rheumatology, 2008
View PDFchevron_right